Evidence map›Paper›PMID 40975795›Full record

ArticleIranian biomedical journal2025

Association of rs4646287 Polymorphism with the Risk of Hepatitis B Virus Infection and the Progression of Hepatocellular Carcinoma in an Iranian Population.

Hassan Akrami, Mohammad Reza Fattahi, Mastaneh Zeraatiannejad, Jamal Sarvari, Yousef Nikmanesh, Zahra Mansourabadi, Zahra Yazdani

Abstract read
In one paragraph

Article in Iranian biomedical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hassan AkramiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza FattahiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mastaneh ZeraatiannejadGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Jamal SarvariDepartment of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Yousef NikmaneshGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra MansourabadiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra YazdaniDepartment of Biology, College of Sciences, Shiraz University, Shiraz 71467-13565, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis B virus (HBV) is responsible for more than one million deaths annually, mainly due to HBV-related diseases and hepatocellular carcinoma (HCC). HBV enters hepatocytes and interacts with the sodium taurocholate co-transporting polypeptide. While several single nucleotide polymorphisms (SNPs) have been linked to HBV infection and HCC, further research is needed to clarify the precise role of SNPs. The relationship of the rs4646287 SNP with the risk of HBV infection and the progression of cirrhosis and HCC has been investigated in different populations. This study aimed to evaluate the association of the rs4646287 SNP with HBV infection, cirrhosis, and HCC in an Iranian population. Methods: The whole blood DNA was extracted from healthy individuals and patients with HBV, cirrhosis, and HCC. Primers for the C and T variants were designed using Primer1. The genotypes of the samples were identified using Tetra-ARMS PCR. The Tetra-ARMS PCR products were analyzed by electrophoresis on 2.5% agarose gels. Results: Individuals with the rs4646287 TT genotype exhibited a significantly reduced risk of developing cirrhosis and HCC compared to healthy controls. The TT genotype also showed a decreased correlation between the HBV group and those with cirrhosis and HCC. Conclusion: Our findings suggest that the rs4646287 TT genotype is associated with a lower risk of developing HBV-related diseases and HCC in an Iranian population. Background: Hepatitis B virus is responsible for more than one million deaths annually, mainly due to HBV-related diseases and HCC. HBV enters hepatocytes and interacts with the NTCP. While several SNPs have been linked to HBV infection and HCC, further research is needed to clarify the precise role of SNPs. The relationship of the rs4646287 SNP with the risk of HBV infection and the progression of cirrhosis and HCC has been investigated in different populations. This study aimed to evaluate the association of the rs4646287 SNP with HBV infection, cirrhosis, and HCC in an Iranian population. Methods: The whole blood DNA was extracted from healthy individuals and patients with HBV, cirrhosis, and HCC. Primers for the C and T variants were designed using Primer1. The genotypes of the samples were identified using Tetra-ARMS PCR. The Tetra-ARMS PCR products were analyzed by electrophoresis on 2.5% agarose gels. Results: Individuals with the rs4646287 TT genotype exhibited a significantly reduced risk of developing cirrhosis and HCC compared to healthy controls. The TT genotype also showed a decreased correlation between the HBV group and those with cirrhosis and HCC. Conclusion: Our findings suggest that the rs4646287 TT genotype is associated with a lower risk of developing HBV-related diseases and HCC in an Iranian population.

Indexed as

Carcinoma, HepatocellularGenetic Predisposition to DiseaseHepatitis BHepatitis B virusLiver NeoplasmsPolymorphism, Single NucleotideAdultCase-Control StudiesDisease ProgressionFemaleHumansIranMaleMiddle AgedRisk FactorsHepatitis B virushepatocellular carcinomasingle nucleotide polymorphisms

Identifiers

PMID40975795
PMCPMC12584340

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.